

Transforming Glomerulonephritis Care Through Emerging Diagnostics and Therapeutics

Tamer A. Addissouky^{1,2,3*}, Ahmed A. Khalil⁴, Ibrahim El Tantawy El Sayed², Majeed M. A. Ali¹, and Yuliang Wang⁵

¹ Al-Hadi University College, Baghdad, Iraq.

² Department of Biochemistry, Science Faculty, Menoufia University, Menoufia, Egypt

³ MLS ministry of health, Alexandria, Egypt. - MLS ASCP, USA.

⁴ Department of Pathology, BayState Medical Center, Springfield, Massachusetts, UNITED STATES.

⁵ Joint International Research Laboratory of Metabolic and Developmental Sciences, Key Laboratory of Urban Agriculture (South) Ministry of Agriculture, Plant Biotechnology Research Center, Fudan-SJTU-Nottingham Plant Biotechnology R&D Center, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.

***Corresponding Author:** Tamer A. Addissouky, Al-HADI University College, Baghdad. Iraq. - Department of Biochemistry, Science Faculty, Menoufia University, Egypt. - MLS ministry of health, Alexandria, Egypt. - MLS, ASCP, USA.

Received Date: January 12, 2024; **Accepted Date:** January 19, 2024; **Published Date:** January 26, 2024

Citation: Tamer A. Addissouky, Ahmed A. Khalil, Ibrahim El Tantawy El Sayed, Majeed M. A. Ali, and Yuliang Wang, (2024). Transforming Glomerulonephritis Care Through Emerging Diagnostics and Therapeutics, *Clinical Medical Reviews and Reports*, 6(2); DOI:10.31579/2690-8794/199

Copyright: © 2024, Tamer A. Addissouky. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Glomerulonephritis refers to a range of conditions involving inflammation and injury to the kidneys' glomeruli, often leading to significant morbidity if left untreated.

Purpose: This review aims to examine emerging advancements in the prevention and treatment of glomerulonephritis, and highlight progress in transforming the prognosis of this spectrum of diseases, while also identifying gaps requiring ongoing effort.

Main body: Novel targeted immunotherapies utilizing engineered delivery platforms and biologicals like monoclonal antibodies are progressing in research pipelines, potentially offering safer, more efficacious alternatives to current standard immunosuppression. High-throughput biomarker assays and AI/machine learning algorithms have demonstrated the ability to improve early detection of kidney damage and guide personalized treatment plans. Further prevention opportunities emerge from modulating microbiome-immune interactions, lifestyle factors, and vaccinations shielding against infections triggering renal disorders.

Conclusion: Although challenges remain, recent advancements in unraveling the pathogenesis of glomerulonephritis coupled with the emergence of cutting-edge diagnostics and targeted interventions set the stage for a new era combating the risk and progression of this spectrum of diseases.

Keywords: glomerulonephritis; diagnostic tools; pharmacological treatments; artificial intelligence; lifestyle interventions; nanomedicine

1. Introduction

Glomerulonephritis refers to inflammation and injury of the glomeruli, the tiny filtration units within the kidneys. It can arise from various causes like infections, autoimmunity, and genetic factors, and may be acute or chronic [1]. Symptoms include blood and protein in the urine, high blood pressure,

and swelling, though manifestations differ. Diagnosis involves exams, lab tests, and imaging studies. Treatment targets the underlying cause, controls symptoms, and prevents complications. Severe disease may require kidney transplant [2]. Glomerulonephritis can lead to chronic kidney disease, end-

stage renal disease, and cardiovascular issues, severely impacting health. Thus, effective prevention and management is crucial, through addressing underlying causes, minimizing risks, and adopting healthy lifestyles [3-6]. Recent advances provide new possibilities, including discovering novel biomarkers, imaging techniques, and personalized medicine, plus exploring artificial intelligence, nanotechnology, and stem cell therapy [7].

However, more research, innovation, and patient education are still needed to maximize these opportunities and develop improved prevention, diagnosis, and treatment approaches. Beyond recent advances, prevention strategies like healthy lifestyles, vaccines, and herbal medicine are also being investigated to reduce disease risk. Conventional treatments like immunosuppressants, plasmapheresis, and transplant remain important options. Emerging evidence suggests the gut microbiome may influence

development and progression, so modulating it is being explored as a prevention and treatment approach [8]. Other promising research directions are stem cell therapy, telemedicine, remote monitoring, patient support programs, and collaborative data networks.

Implementing these advances faces challenges including costs, integration into healthcare systems, ensuring access and efficacy, and sustainability. A collaborative, comprehensive effort among stakeholders is required to overcome these hurdles and realize the goal of improving prevention, diagnosis, and treatment of this disease [9]. As presented in **figure 1**, this review examines emerging innovations in combating glomerulonephritis, highlighting progress in comprehending pathogenesis and harnessing tools like nanotechnology and artificial intelligence to pave the pathway to enhanced outcomes.




Figure (1) Glomerulonephritis Disease Management and Prevention Through Recent Advances and Innovative Approaches.

II. Prevention of glomerulonephritis Diseases

Glomerulonephritis, if untreated, can progress to kidney failure. While treatments exist, prevention is the optimal approach. Maintaining a healthy lifestyle, managing underlying conditions, preventing infections, avoiding toxins, and considering herbal medicine are prevention strategies for glomerulonephritis.

II.1. Novel diagnostic tools for glomerulonephritis diseases

Glomerulonephritis inflames/damages glomeruli, resulting in symptoms/complications. Early accurate diagnosis is key for treating glomerulonephritis. Recently, novel diagnostic tools emerged including biomarkers, imaging, AI applications, advancing glomerulonephritis understanding as depicted in **table 1**. Such innovations potentially enhance diagnostic precision, recognize subtypes, foresee progression. Additionally, these tools may assist personalized therapy development [10].

Technology	Description	Applications	Limitations
AI/ML	Algorithms analyzing patient data	Earlier diagnosis; treatment personalization	Algorithm accuracy; equitability
Biomarkers	Measurable indicators of disease state	Detect early kidney injury; indicate subtype	Lack standardization, specificity
POCT	Rapid diagnostics at point of care	Screen for proteinuria, assess kidney function	Restricted in information gained
Advanced imaging	Novel scans visualizing kidney changes	Identify early structural alterations	Expensive equipment required

Table 1: Emerging diagnostic approaches for glomerulonephritis

II.1.1. Artificial intelligence and machine learning:

Artificial intelligence (AI) and machine learning (ML) are being increasingly explored for their potential in aiding the early detection and diagnosis of glomerulonephritis, a kidney disease that can lead to kidney failure if left untreated. AI and ML algorithms can analyze large amounts of data from various sources, such as electronic health records, imaging studies, and laboratory tests, to identify patterns and make predictions about disease progression. By leveraging these technologies, healthcare providers may be able to detect glomerulonephritis earlier, identify disease subtypes, and develop personalized treatment plans for patients. However, there are challenges to overcome, such as ensuring the accuracy and reliability of AI and ML algorithms, addressing ethical considerations, and ensuring equitable access to these technologies [11].

II.1.2. Biomarkers:

Recently, significant progress has been made in the identification and validation of novel biomarkers for the early detection of glomerulonephritis. These biomarkers, which can be detected in blood, urine, or tissue samples, provide insights into disease pathogenesis, identify disease subtypes, and predict disease progression. One example of a protein biomarker is neutrophil gelatinase-associated lipocalin (NGAL), a protein that is upregulated in the setting of kidney injury. NGAL has been shown to be a potential biomarker for the early detection of acute kidney injury and has also been explored as a biomarker for various types of glomerulonephritis, including IgA nephropathy and lupus nephritis. Another example of a biomarker is microRNA-29c, which has been identified as a potential biomarker for diabetic nephropathy, a type of glomerulonephritis associated with diabetes [12]. MicroRNA-29c is involved in the regulation of extracellular matrix proteins, which play a role in the development of diabetic nephropathy. Metabolites such as TMAO and hippurate have also been identified as potential biomarkers for glomerulonephritis. TMAO is produced by gut bacteria and has been implicated in the development of cardiovascular disease and kidney injury. Hippurate, a metabolite produced during the breakdown of amino acids, has been shown to be elevated in patients with IgA nephropathy [13].

II.1.3. Point-of-care testing:

Point-of-care testing (POCT) is a convenient and efficient diagnostic method that enables rapid diagnosis and monitoring of diseases at the patient's bedside. In the case of glomerulonephritis, POCT offers an effective and cost-efficient approach for early detection and disease progression monitoring. For instance, the urine dipstick test can detect protein and blood in urine samples, indicating kidney damage and the need for further testing. This readily available and affordable test serves as a practical screening tool for glomerulonephritis. Measuring serum creatinine levels, which estimate glomerular filtration rate (GFR), is another POCT example used to diagnose and monitor glomerulonephritis. Handheld devices enable the rapid and convenient assessment of serum creatinine levels. Additionally, POCT utilizing biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL), shows promise for the early detection of glomerulonephritis. NGAL testing devices have been developed and demonstrate potential for detecting acute kidney injury and various glomerulonephritis types [14].

II.1.4. Glomerulonephritis imaging:

Significant advancements have been made in the development of novel diagnostic imaging tools for early detection of glomerulonephritis. These tools offer non-invasiveness, high sensitivity, and specificity, enabling timely intervention. Contrast-enhanced ultrasound (CEUS) uses microbubble injection to enhance contrast between blood vessels and tissues, providing information on kidney perfusion. CEUS detected changes in kidney perfusion in IgA nephropathy patients before conventional ultrasound [15]. Diffusion-weighted magnetic resonance imaging (DW-MRI) measures water molecule diffusion, revealing microstructural changes in the kidneys. DW-MRI detected early glomerulonephritis changes in IgA nephropathy patients before conventional MRI. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are also being explored for early glomerulonephritis detection, utilizing radioactive tracers to assess cellular activity and metabolism in the kidneys [16].

Limitations and challenges of Novel diagnostic tools:

Novel diagnostic tools for glomerulonephritis hold promise but have limitations including standardization, specificity, accessibility, required training/expertise, data interpretation complexity, cost, validation requirements, ethical issues, variable patient acceptance, and clinical workflow integration challenges. Standardization is needed for reproducibility but lack thereof impedes adoption. Many biomarkers lack specificity to accurately diagnose/monitor glomerulonephritis. Some tools like imaging require expensive specialized equipment restricting accessibility. Advanced techniques demand specialized training unavailable in resource-limited settings. Non-experts find artificial intelligence/machine learning results difficult to understand for patient care. Cost prohibits some biomarker assays' accessibility. Validation establishes accuracy/reliability but takes time and money. Genetic testing raises discrimination concerns if privacy/appropriate care are unaddressed. Lengthy scans/injections receive less acceptance. Providers require training on novel tools' clinical incorporation [17].

II.2. Lifestyle modifications

While medical treatment is essential for managing glomerulonephritis, lifestyle modifications can also play an important role in preventing and managing the disease. Lifestyle modifications may include dietary changes, exercise, smoking cessation, stress management, alcohol consumption, and medication adherence. These modifications can help manage blood pressure, reduce inflammation, prevent further kidney damage, and improve overall health as depicted in **table 2**. Adopting a healthy lifestyle can be particularly important for patients with glomerulonephritis, as they are at increased risk of complications such as high blood pressure, cardiovascular disease, and kidney failure. In this way, lifestyle modifications can be an important part of a comprehensive approach to managing and preventing glomerulonephritis. In addition to medical treatment, lifestyle modifications can play an important role in managing glomerulonephritis and improving overall health [18]. Some lifestyle modifications that can be beneficial for patients with glomerulonephritis include:

Risk Factor	Description	Impact on Disease Risk/Progression
Diet	High sodium, fat, protein; low potassium, fluids	Increases inflammation, BP; accelerates kidney damage
Physical inactivity	Lack of regular exercise	Worsens CVD risk; reduces kidney function
Smoking	Cigarette smoking	Accelerates kidney function decline

Risk Factor	Description	Impact on Disease Risk/Progression
Stress	Chronic psychological stress	Raises BP, inflammation; damages kidneys
Alcohol	Excessive intake	Increases BP, liver toxicity; harmful to kidneys
Medication non-adherence	Not taking Rx as directed	Leads to uncontrolled disease, faster progression

Table 2: Modifiable lifestyle risk factors for glomerulonephritis

II.2.1. Diet and nutrition

Dietary changes can be an important component of managing glomerulonephritis. A healthy diet may help manage blood pressure, reduce inflammation, and prevent further kidney damage. Patients with glomerulonephritis may benefit from a low-sodium, low-fat, and low-protein diet, along with limiting potassium and phosphorus and staying hydrated. Foods high in sodium, such as processed and canned foods, should be avoided, while healthy fats found in nuts, seeds, and fatty fish can be consumed in moderation. Patients should also aim to consume between 0.6 and 0.8 grams of protein per kilogram of body weight per day and choose high-quality protein sources such as lean meats, fish, and plant-based proteins. In addition to dietary changes, patients with glomerulonephritis should consult with a registered dietitian to develop a personalized nutrition plan that meets their individual needs and preferences [19].

II.2.2. Exercise and physical activity

Regular exercise is an important lifestyle modification for patients with glomerulonephritis. Exercise can help manage blood pressure, improve cardiovascular health, and reduce inflammation, which are all important for managing the disease. Patients with glomerulonephritis should aim to incorporate aerobic exercise, strength training, or low-impact exercises such as yoga or tai chi into their daily routine, as recommended by their healthcare provider. Aerobic exercise, such as brisk walking, cycling, or swimming, can improve cardiovascular health and reduce inflammation. Strength training, such as weightlifting or resistance band exercises, can build muscle mass and improve overall fitness. Low-impact exercises such as yoga or tai chi can reduce stress, improve flexibility, and improve balance [20].

II.2.3. Smoking cessation

For patients with glomerulonephritis, smoking cessation is a crucial lifestyle modification. Smoking can worsen kidney function and increase the risk of cardiovascular disease, which are common complications of glomerulonephritis. Quitting smoking can help improve overall health and reduce the risk of complications associated with the disease. Smoking cessation can improve kidney function, reduce inflammation, lower blood pressure, and decrease the risk of complications such as heart disease, stroke, and kidney failure [21].

II.2.4. Stress management

For patients with glomerulonephritis, stress management is an important aspect of lifestyle modification. Stress can exacerbate kidney function and increase the risk of complications such as high blood pressure and cardiovascular disease. Patients with glomerulonephritis can manage stress by adopting various strategies like mind-body techniques, exercise, social support, and time management. Mind-body techniques such as meditation, yoga, and deep breathing exercises can help reduce stress and promote relaxation. Exercise is an effective stress management technique that can reduce tension and promote relaxation. Social support from family, friends, or support groups can help reduce stress and promote emotional well-being. Effective time management can help reduce stress and improve productivity [22].

II.2.5. Alcohol consumption

Alcohol consumption is a lifestyle factor that patients with glomerulonephritis should manage carefully. Excessive alcohol consumption can worsen kidney function, increase blood pressure, and lead to complications such as liver disease and heart disease [23-29]. Patients with glomerulonephritis should limit alcohol intake to no more than one drink per day for women and two drinks per day for men. They should also avoid binge drinking, which is defined as consuming more than four drinks for women and five drinks for men in a single session. By managing alcohol consumption effectively, patients with glomerulonephritis can reduce the risk of complications associated with the disease. Limiting alcohol intake and avoiding binge drinking can help prevent worsening of kidney function and increase in blood pressure [30].

II.2.6. Medication adherence

Medication adherence is a crucial aspect of managing glomerulonephritis. Patients with glomerulonephritis may require medications to manage blood pressure, reduce inflammation, and prevent complications. Non-adherence to medication regimens can lead to worsening of the disease and an increased risk of complications. Patients with glomerulonephritis can improve medication adherence by understanding the importance of medication, simplifying medication regimens, setting reminders, and engaging in patient education. Healthcare providers can provide support and resources to help patients adhere to their medication regimen effectively [31].

II.3. Pharmacological interventions

Pharmacological interventions are a critical component of managing glomerulonephritis. Medications may be used to manage blood pressure, reduce inflammation, and prevent complications. The choice of medication depends on the underlying cause of glomerulonephritis, the severity of the disease, and the patient's medical history. Common medications used to treat glomerulonephritis include Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), immunosuppressants, diuretics, and anticoagulants. These medications work by dilating blood vessels, suppressing the immune system, increasing urine output, and preventing blood clots [32]. Some common medications used to treat glomerulonephritis include:

II.3.1. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are commonly used medications to manage blood pressure and reduce proteinuria in patients with glomerulonephritis. These medications work by dilating blood vessels and reducing stress on the kidneys. ACE inhibitors and ARBs are particularly effective in patients with glomerulonephritis who have proteinuria, which is a common complication of the disease. ACE inhibitors and ARBs work by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure. By blocking the action of angiotensin II, these medications can dilate blood vessels and reduce blood pressure, which can reduce stress on the kidneys. ACE inhibitors and ARBs can also reduce proteinuria by reducing the amount of protein that is filtered through the kidneys. These

medications may also have other beneficial effects, such as reducing inflammation and improving endothelial function [33].

II.3.2. Immunosuppressants:

Immunosuppressants are medications that may be used to manage glomerulonephritis by reducing inflammation and preventing damage to the kidneys. Corticosteroids and cytotoxic agents are common immunosuppressants used in the treatment of glomerulonephritis. These medications work by suppressing the immune system, which can reduce inflammation and prevent further damage to the kidneys. Corticosteroids such as prednisone are commonly used to manage glomerulonephritis. They work by reducing inflammation and suppressing the immune response. Cytotoxic agents such as cyclophosphamide and azathioprine may also be used to manage glomerulonephritis. These medications work by inhibiting the growth of cells that contribute to inflammation and damage to the kidneys [34].

II.3.3. Diuretics:

Diuretics are medications that may be used to manage fluid retention and reduce blood pressure in patients with glomerulonephritis. Diuretics work by increasing urine output and reducing the amount of fluid in the body. This can help reduce swelling, shortness of breath, and other symptoms associated with fluid retention. Loop diuretics such as furosemide are commonly used in the treatment of glomerulonephritis. These medications work by inhibiting the reabsorption of sodium and chloride in the ascending loop of Henle in the kidneys, which can increase urine output and reduce fluid retention. Thiazide diuretics such as hydrochlorothiazide may also be used in the treatment of glomerulonephritis. These medications work by inhibiting the reabsorption of sodium and chloride in the distal tubules of the kidneys, which can also increase urine output and reduce fluid retention [35].

II.3.4. Anticoagulants:

Anticoagulants are medications that may be used to prevent blood clots in patients with glomerulonephritis who are at risk of developing thromboembolic complications. Thromboembolic complications, such as deep vein thrombosis and pulmonary embolism, are a significant risk for patients with glomerulonephritis due to the underlying inflammation and damage to blood vessels. Anticoagulants work by inhibiting the formation of blood clots, which can reduce the risk of thromboembolic complications. Warfarin and heparin are commonly used anticoagulants in the treatment of glomerulonephritis. Warfarin works by inhibiting the production of vitamin K-dependent clotting factors in the liver, which can prevent the formation of blood clots. Heparin works by inhibiting the activity of clotting factors in the blood, which can also prevent the formation of blood clots [36].

II.4. Innovative approaches of Prevention:

The prevention of glomerulonephritis involves controlling risk factors and reducing inflammation to prevent damage to the kidneys. Recent advances in innovative approaches for the prevention of glomerulonephritis include lifestyle modifications, vaccinations, probiotics, anti-inflammatory agents, and genetic screening and counseling. Lifestyle modifications such as regular exercise, maintaining a healthy weight, and quitting smoking have been shown to reduce the risk of developing glomerulonephritis. Vaccinations against infections that can trigger the disease, such as hepatitis B virus (HBV), can also help prevent glomerulonephritis. Probiotics have been suggested to have a role in preventing glomerulonephritis by reducing inflammation and protecting against infections. Anti-inflammatory agents like omega-3 fatty acids, colchicine, and pentoxifylline have shown promise in preventing the development of glomerulonephritis [37].

II.4.1. Genetic testing and risk stratification:

Genetic screening constitutes analyzing a person's DNA recognizing changes potentially related to elevated renal disorder or condition probability. Danger stratification identifies higher-hazard individuals reliant on age, sex, ancestraleced history, and hereditary predisposition. Regarding renal sickness, genetic screening can recognize persons with amplified chance developing selective glomerulonephritis for example Alport syndrome or Fabry disease caused by particular mutations. Early identification enables targeted observation and therapy forestalling or postponing disease starting. Beyond genetic screening, extra chance aspects contain autoimmune or contamination histories, ecologic toxic exposure, and some medicaments [38].

II.4.2. Targeted prevention strategies:

Focused risk mitigation techniques aim reducing unique condition likelihood by concentrating on elevated chance persons owing to hereditary, environmental, or lifestyle aspects. Regarding glomerulonephritis, centered deterrents can spot and oversee higher renal disease danger individuals because of particular chance elements. One methodology identifies genetic anomalies raising renal illness probability. Genetic screening determines mutation carriers facilitating targeted supervision and treatment forestalling or postponing disorder debut, as subjects with a relatives history of Alport syndrome potentially confronting screening to distinguish related mutations. Another centers controlling causative autoimmune or contamination states contributory to development, for example lupus patients facing individualized immunosuppression to decrease irritation and preclude organ harm [39].

II.4.3. Use of mobile health technology

Mobile health technology, regarded as mHealth, represents a swiftly developing field deploying portable devices like smartphones and tablets delivering medical care and information. Regarding glomerulonephritis prevention, mHealth acts as an instrument promoting healthful behaviors, monitoring risk determinants, and offering education and backing to those vulnerable developing the condition. mHealth can promote prevention employing apps motivating workouts, nutritional balance, and smoking cessation providing customized recommendations and tracking assistance maintaining health targets. An additional mHealth prevention function involves mobile monitoring of determinants including hemodynamic and glucose employing transmitted data enabling providers targeted intercession for individuals vulnerable developing renal illness. Education and backing may disseminate through texting services and online discussions relaying prevention information and encouragement amid lifestyle changes decreasing condition danger. mHealth technologies may also improve care accessibility for those remote or underserved possibly confronting barriers accessing traditional providers using telemedicine permitting remote supervision and consultation [40].

III. Management of Glomerulonephritis Diseases

The management of glomerulonephritis can be classified into acute and chronic forms, each requiring different strategies to manage the disease. Acute glomerulonephritis may involve treating underlying infections or autoimmune disorders that trigger the disease, controlling symptoms such as high blood pressure and excess fluid retention, and preventing complications such as kidney failure. In contrast, chronic glomerulonephritis may involve a combination of medications, lifestyle modifications, and regular monitoring to slow or stop the progression of kidney damage, manage symptoms, and prevent complications such as kidney failure.

III.1. Acute management

Acute management of glomerulonephritis involves treating sudden and severe kidney damage and preventing complications. Some of the key strategies for acute management may include:

III.1.1. Immunosuppressive therapy for acute exacerbations

Immunosuppressive therapy constitutes a management approach suppressing the immune system and reducing corporeal inflammation. Regarding glomerulonephritis, immunosuppressive therapy commonly handles exaggerated disease episodes potentially instigating abrupt, grievous renal detriment. During exacerbations, immunological hyperactivation attacks glomeruli, leading to inflammation and harm. Immunosuppressive therapy functions suppressing immunological responses, reducing inflammation, and minimizing additional renal injury. Regularly used immunosuppressants encompass corticosteroids like prednisone and agents consisting of cyclophosphamide and azathioprine, singly or bundled reliant on causation and symptom seriousness. Immunosuppressive therapy's employment amid acute glomerulonephritis exacerbations usually proves effectual in inflammation reduction and subsequent renal harm prevention [41].

III.1.2. Management of nephrotic syndrome

Nephrotic syndrome constitutes a condition typified by amplified urinary protein, diminished serum protein, and edema affecting diverse body regions. Management may couple medications and lifestyle modifications. Medications can include diuretics reducing surplus fluid and edema, ACE inhibitors or ARBs controlling hemodynamic and lessening proteinuria, and immunosuppressants suppressing inflammation. Corticosteroids like prednisone frequently treat nephrotic syndrome causally relating to minimal change disease. Additional immunosuppressants may treat relying on root causation. Lifestyle changes can encompass diminished sodium diet, workout, and smoking cessation. A restricted protein diet may reduce renal workload. Close surveillance of renal performance and proteinuria proves essential treatment assessment and modification [42].

III.1.3. Treatment of acute kidney injury

Acute kidney injury constitutes an abrupt, severe kidney detriment developing from diverse root causes like glomerulonephritis. AKI administration may involve supportive care for instance dialysis, in addition to managing causative states including contaminations or autoimmune conditions potentially precipitating the occasion. Medications may also regulate hemodynamic and fluid preservation symptoms. Dialysis presents a prevalent AKI treatment particularly when kidneys fail removing waste and surplus fluid. Dialysis employs machinery filtering waste and extra fluid from blood. Principal dialysis varieties encompass hemodialysis utilizing an apparatus externally and peritoneal dialysis exploiting the abdominal lining internally. Beyond dialysis, medications can control hemodynamic, fluid preservation, and electrolyte imbalance symptoms. Reliant on root causation, treatments like antibiotics or immunosuppressants may handle the circumstance. Hospitalization sometimes proves necessary for close supervision and issue management, distinctly for severe AKI threatening dehydration or electrolyte imbalances [43].

III.2. Chronic management

Chronic management of glomerulonephritis involves ongoing care and treatment to slow the progression of kidney damage and prevent complications. Some of the key strategies for chronic management may include:

III.2.1. Medical therapy for chronic kidney disease:

Medical care for chronic kidney disease aims slowing organ harm progression, symptom management, and complication avoidance. Key strategic methodologies may encompass:

Hemodynamic regulation: Elevated blood pressure commonly arises with CKD and can amplify harm, treated using agents like ACE inhibitors or ARBs lowering pressure and damage prospects [44].

Proteinuria management: Proteinuria also regularly emerges, potentially treated by SGLT-2 inhibitors, ACE inhibitors or ARBs reducing proteinuria and slowing organ deterioration. Anemia mitigation: As anemia commonly develops due to CKD, erythropoietin-stimulating agents may treat fatigue and weakening [45].

Bone disease administration: CKD contributes to low bone mass and fracture probability, treated using supplements like vitamin D and phosphate binders. CKD also imbalances electrolytes including potassium, addressed using diuretics and potassium binders. CKD additionally stems from underlying disorders like diabetes and autoimmunity. Treating causative conditions proves important management [46].

III.2.2. Dialysis and renal replacement therapy

Dialysis and renal replacement therapy constitute management approaches for individuals with progressed chronic kidney disease or renal failure. These techniques aim replacing renal roles through eliminating waste and surplus fluid. Principal dialysis types include hemodialysis employing machinery to filter blood externally while peritoneal dialysis utilizes the abdominal lining for internal blood filtering. Hemodialysis commonly occurs at dialysis facilities or hospitals contrasting peritoneal dialysis's domestic performance. Renal replacement therapy may also involve kidney transplantation substituting the diseased organ with a healthy donor kidney. Transplantation usually follows dialysis inefficacy or tolerance inability [47].

III.2.3. Kidney transplantation

Kidney transplantation constitutes a management approach for individuals with progressed chronic kidney disease or renal failure. This involves replacing the diseased kidney with a healthy donor kidney. Kidney transplantation can better symptoms, prolong endurance, and progress quality of life for those with renal failure. Donor categories encompass living and deceased [48]. Living donors include relatives, friends, or compatible strangers, while deceased donors consist of individuals consenting to organ donation post-mortem. Prior to transplantation, patients undergo testing to gauge suitability, potentially comprising blood analyses, imaging studies, and mental examinations. Recipients also confront evaluation to pinpoint optimum immunosuppressive treatment preventing transplant rejection. Post-transplantation, lifelong immunosuppressant therapy ensures rejection prevention of the transplanted kidney, as close monitoring of renal performance and drug levels guarantees effective administration [49].

III.3. Innovative approaches of Management

There are several innovative approaches to the management of glomerulonephritis that are currently being studied. Some of these approaches include:

III.3.1. Precision medicine and personalized treatment:

Precision medication and individualized treatment constitute evolving medical methodologies increasingly employed in glomerulonephritis administration. These approaches aim to customize care reliant on one's singular genetic, environmental, and lifestyle factors bettering outcomes and lowering side effect risks. In glomerulonephritis, precision medication involves employing genetic screening and progressive diagnostic tools recognizing root causes in individual patients. By identifying specific genetic anomalies or biomarkers contributory to disease, providers can devise individually-tailored plans targeting causative pathologies. As an example, genetic testing may disclose a mutation amplifying glomerulonephritis risk, allowing customized treatment homing in on this. Personalized

glomerulonephritis treatment may necessitate modifying dosage or medication class reliant on age, weight, renal function, and additional factors. Providers may adjust immunosuppressant amounts predicated on renal proficiency lessening side effect risks. Individualized treatment may also involve lifestyle changes like nutritional modifications or workouts customized to one's precise needs and preferences [50].

III.3.2. Use of artificial intelligence in diagnosis and treatment

Artificial intelligence represents an innovative healthcare methodology using computational algorithms and machine learning to analyze large data volumes, generating insights bettering diagnosis and care. In glomerulonephritis management, AI may assess patient documentation, identifying patterns assisting providers in more accurate diagnoses and effective treatment planning. AI can aid glomerulonephritis identification by examining patient test results like blood analyses, urine screenings, and imaging studies to identify biomarker patterns associated with the disease [51]. As an example, AI may recognize unique biomarkers in blood or urine correlating with glomerulonephritis, allowing more accurate diagnoses. AI may also facilitate individualized treatment planning for glomerulonephritis patients. Through analyzing patient documentation, AI algorithms can recognize the most effective medications and dosages for particular patients dependent on age, weight, renal function, and additional medical conditions. This assists providers devising treatment optimized for individual needs and circumstances aiming to better outcomes and lessen side effects. Beyond diagnosis and treatment, AI may also advance outcomes by forecasting disease progression and recognizing high-risk complication cases [52].

III.3.3. Advances in regenerative medicine

Regenerative medicine represents an interdisciplinary field aiming to restore or substitute harmed or diseased tissues and organs applying progressive biological and engineering techniques. Recent years have witnessed significant advances in regenerative medicine potentially revolutionizing glomerulonephritis care [53]. A promising regenerative medication approach involves deploying stem cells to repair or regenerate damaged renal tissue. Stem cells constitute undifferentiated cells capable of evolving into discrete cell-types, including kidney cells. Analysts are examining stem cell utilization to mend harmed glomeruli, tiny vasculatures accountable for blood waste product filtering. Early investigations demonstrated promising consequences, suggesting stem cell therapy might constitute an effective glomerulonephritis treatment. An additional promising regenerative medication approach involves tissue engineering's development of artificial kidneys or renal tissue. Tissue engineering applies scaffolds and materials creating three-dimensional structures mimicking natural tissue composition and roles. Analysts are exploring tissue engineering's formation of artificial glomeruli and other renal structures to substitute damaged tissue in glomerulonephritis patients [54].

IV. Future Directions and Challenges

The future of managing glomerulonephritis is promising, with ongoing research and advancements in understanding the disease and potential treatments. There are several future directions and challenges that must be considered in the management of this disease:

IV. 1. Emerging therapies and technologies

Emerging therapies and technologies have the potential to revolutionize the management of glomerulonephritis as depicted in **table 3**. Some of the most promising emerging therapies and technologies include:

Therapy/Technology	Description	Mechanism of Action	Status/Challenges
Gene therapy	Introduces genetic material to treat disease	Corrects genetic mutations driving disease progression	Early research stage, challenges with delivery and safety
Stem cell therapy	Uses stem cells to regenerate damaged kidney tissue	Stem cells differentiate into kidney cells to replace damaged tissue	Early research, challenges with ensuring cell potency and preventing rejection
Biological therapies (monoclonal antibodies, immunomodulators)	Drugs targeting immune mediators involved in kidney damage	Bind complement proteins, cytokines; modulate immune cells	Some in clinical trials, high costs, side effects
Nanomedicine	Utilizes nanoscale materials for targeted diagnosis/treatment	Small size enhances tissue penetration; modular design enables precision delivery	Early research stage, manufacturing hurdles, toxicity concerns

Table 3: Emerging therapies and technologies for glomerulonephritis management

IV.1.1. Gene therapy

Gene therapy has emerged as a prospective new technique for glomerulonephritis management. Gene therapy involves introducing genetic material into cells to remedy or avert disease. In glomerulonephritis management, gene therapy could rectify genetic mutations contributory to the disease's progression. One possible target for gene therapy in glomerulonephritis management includes the complement system, a protein group implicated in the immune system and kidney damage development in glomerulonephritis. Researchers are exploring employing gene therapy to introduce genes regulating the complement system and preventing renal injury. An additional potential target for gene therapy in glomerulonephritis management involves the podocyte, a specialized renal cell accountable for

filtering waste from the blood. Podocyte malfunction can contribute to glomerulonephritis creation. Analysts are investigating using gene therapy to introduce genes promoting podocyte functions and inhibiting kidney injury [55].

IV.1.2. Stem cell therapy

Stem cell therapy shows potential as a method for glomerulonephritis management. Stem cells are undifferentiated cells capable of maturing into distinct cell-types, including renal cells. In glomerulonephritis management, stem cell therapy could repair or regenerate harmed kidney tissue. One prospective source of stem cells for glomerulonephritis treatment involves the patient's own bone marrow contents. Bone marrow houses stem cells with the capacity to evolve into renal cells, and analysts are exploring employing

these cells to reconstruct damaged glomeruli and other renal structures. Another possible source of stem cells for glomerulonephritis treatment consists of induced pluripotent stem cells. Induced pluripotent stem cells result from reprogramming adult cells into an embryonic stem cell-like condition and can develop into kidney cells. Researchers are investigating using induced pluripotent stem cells to bioengineer artificial glomeruli and other renal structures for replacing damaged tissue in glomerulonephritis cases [56].

IV.1.3. biological therapy

Biological therapy has emerged as a prospective approach for glomerulonephritis management. Biological therapies involve drugs produced from living organisms or their products intended to focus immunologic mechanisms contributory to glomerulonephritis development and progression. Monoclonal antibodies represent one category of biological therapy exhibiting promise for glomerulonephritis management. Monoclonal antibodies comprise laboratory-formulated molecules able to target specific immune proteins. In glomerulonephritis management, monoclonal antibodies can home in on complement system proteins or other immunological elements linked to kidney injury. Immunomodulating agents constitute another classification of biological therapy displaying possibility for glomerulonephritis management. Immunomodulating drugs modify the immune system to avert or handle disease. In glomerulonephritis management, immunomodulating drugs can suppress the immune system and inhibit additional harm to the kidneys [57].

IV.1.4. Complement inhibitors

Complement inhibitors hold promise as drugs for managing glomerulonephritis, a condition where the complement system contributes to kidney damage. Eculizumab, a monoclonal antibody targeting C5, has shown potential in reducing kidney damage by inhibiting complement system activation. C1 inhibitor, a protein regulating the complement system, is also being explored as a glomerulonephritis treatment [58].

IV.1.5. Nanotechnology

Nanotechnology, utilizing nanoscale materials and devices, has shown promise in the management of glomerulonephritis. Recent advancements include targeted drug delivery, nanosensors for early detection of kidney damage, nanoscale imaging techniques, nanoparticle-based immunotherapy, gene therapy, immunomodulation, and biomaterials for tissue repair [59-61]. These innovations aim to enhance drug efficacy, minimize side effects, detect kidney damage early, provide real-time monitoring, deliver genetic material precisely, modulate immune responses, and regenerate kidney tissue. Nanoscale imaging techniques aid in identifying early signs of kidney damage and monitoring disease progression. However, challenges encompass safety concerns, manufacturing obstacles, regulatory and ethical considerations, targeting efficiency, and immune system clearance [62-66].

IV.1.6. vaccination

Vaccination is a crucial preventive strategy against glomerulonephritis, which can result from infections like streptococcal infections that trigger immune responses causing kidney damage. Vaccines can prevent such infections and decrease the risk of glomerulonephritis [67]. For instance, the pneumococcal vaccine combats *Streptococcus pneumoniae*, a common cause of respiratory infections and potential glomerulonephritis inducer. Similarly, the influenza vaccine prevents influenza virus infections that can lead to glomerulonephritis. While vaccination doesn't cure existing kidney damage, it averts further injury and complications. Furthermore, vaccines protect against other infections like hepatitis B virus and human papillomavirus, which can also cause glomerulonephritis. Particularly important for high-risk

individuals with chronic kidney disease or diabetes, vaccination is a safe and effective public health measure to reduce glomerulonephritis burden and improve outcomes, despite limitations such as effectiveness, access, hesitancy, booster doses, and inability to reverse kidney damage [68-69].

IV.1.7. probiotics and gut microbiome

The intestinal microbiota plays an important role in regulating the immune system's advancement and modulation [70]. Moreover, disturbances in the intestinal microbiota may contribute to the pathogenesis of glomerulonephritis. Probiotics, which are live microorganisms that can provide benefits to health when adequately consumed, have been proposed as a potential therapy for glomerulonephritis through modulation of both the intestinal microbiota and immune system. Animal and human clinical investigations have demonstrated probiotics' ability to modulate the immune system and decrease the severity of kidney damage in glomerulonephritis. For example, research in rats with glomerulonephritis found treatment with *Lactobacillus rhamnosus* GG enhanced renal function and reduced inflammation and scarring in the kidneys. Another study in humans with IgA nephropathy, a type of glomerulonephritis, revealed treatment with a probiotic containing *Lactobacillus acidophilus*, *Bifidobacterium bifidum*, and *Streptococcus thermophilus* decreased proteinuria, a key biomarker of kidney injury. Probiotics have exhibited promise for glomerulonephritis management but limitations and challenges remain, such as restricted understanding of the intestinal microbiota's role in glomerulonephritis pathogenesis and probiotics' mechanisms of action [71].

IV.1.8. herbal and traditional medicine

A growing body of research has identified various herbs and compounds with anti-inflammatory and antioxidant properties that may help reduce kidney damage and inflammation in glomerulonephritis. For example, curcumin and resveratrol, two compounds found in turmeric and grapes respectively, have been shown to reduce inflammation and oxidative stress in the kidneys and may help prevent or manage glomerulonephritis. Traditional Chinese herbal formulas have also been studied for their potential benefits in reducing proteinuria and improving kidney function in glomerulonephritis [72-73]. *Flos Abelmoschus manihot* and *Flos Carthami* are two herbs commonly used in traditional Chinese medicine that have shown promising results in reducing proteinuria and improving kidney function in patients with glomerulonephritis. Another recent advance in herbal medicine for the management of glomerulonephritis is the use of *Centella asiatica*, a herb commonly used in Ayurvedic medicine. A study in rats with glomerulonephritis found that a compound derived from *Centella asiatica* was able to reduce kidney damage and inflammation. However, there are also limitations and challenges to consider, such as limited scientific evidence, lack of standardization, potential for adverse effects, lack of regulation, and inter-individual variability [74].

IV.1.9. telemedicine

Telemedicine is an innovative healthcare delivery approach that utilizes technology for remote medical care and consultation. It has gained popularity and has the potential to revolutionize healthcare, especially for patients with glomerulonephritis. Telemedicine offers multiple benefits for managing glomerulonephritis, including improved access to care for patients living in rural or remote areas, increased convenience by eliminating the need for travel, enhanced patient outcomes through increased engagement and adherence, reduced healthcare costs by avoiding hospital stays and emergency visits, and improved provider collaboration for better coordination and quality of care. Despite challenges such as reimbursement and regulatory barriers, telemedicine is expected to address these concerns

and become a valuable tool in managing chronic conditions like glomerulonephritis [75].

IV.2. General challenges in implementing new advances

Implementing advances in glomerulonephritis poses challenges including cost limiting patient access, infrastructure changes needing electronic medical records upgrades, personnel training, protocol adoption, clinical resistance to unfamiliar technologies/therapies, prolonged regulatory approval delaying availability, data privacy/security risk necessitating protection, and variable patient acceptance depending on uncertainties surrounding technologies, treatments, side effects or risks. General barriers involve significant financial investments, healthcare restructuring, overcoming reluctance to transition, ensuring protections amid digital transitions, and addressing unfamiliarity with novelties. Strategies addressing these impediments can help translate scientific innovations into optimized clinical application benefiting patients [76].

IV. Conclusion

Glomerulonephritis constitutes a complex spectrum of immune-mediated renal disorders instigating significant morbidity. Recent scientific advancements proffer optimism, with innovations in comprehension of immunopathogenesis and microbiome contributions plus progressive treatments like nanomedicines and AI disease modeling exhibiting prospect transforming prevention and care. However realization of this promise necessitates surmounting hurdles encompassing definitive causation elucidation, diagnostic standardization, therapy optimization balancing efficacy and safety, supportive care delivery model evolution, and addressing associated health disparities. Ultimately comprehending precise disease mechanisms and translating findings into enhanced personalized interventions can accomplish improved outcomes, underscoring the value of ongoing investigation.

V. Recommendations

Realizing glomerulonephritis' disease burden reduction mandates a multifaceted approach targeting refined understanding of pathogenesis for directed treatments, early accurate diagnosis, and comprehensive preventative strategies. Attaining these objectives warrants expanded research on genetic and environmental contributions, microbiome and immune system interplay, deploying progressive technologies like AI and nanomedicine, plus validating and implementing emerging biomarkers, therapies, and multidisciplinary care models. Additionally beyond novel diagnostic and therapeutic innovations, equally crucial elements include advancing screening protocols, disease education, and lifestyle/dietary modifications for primordial and primary prevention among susceptible populations. Finally ensuring equitable access and affordable delivery of existing and new tools can maximize impact on this disease's rising incidence. Ultimately a collaborative framework integrating these components across research, policy, public health, and clinical spheres can achieve improved patient quality of life and societal benefits.

List of abbreviations

ACE - Angiotensin-converting enzyme

AKI - Acute kidney injury

AI - Artificial intelligence

ARBs - Angiotensin receptor blockers

CEUS - Contrast-enhanced ultrasound

CKD - Chronic kidney disease

DW-MRI - Diffusion-weighted magnetic resonance imaging

GFR - Glomerular filtration rate

HBV - Hepatitis B virus

ML - Machine learning

mHealth - Mobile health

NGAL - Neutrophil gelatinase-associated lipocalin

PET - Positron emission tomography

POCT - Point-of-care testing

SPECT - Single-photon emission computed tomography

SGLT-2 - Sodium-glucose co-transporter 2

TMAO - Trimethylamine-N-oxide

Declarations:

Ethics approval and consent to participate: Not Applicable

Consent for publication: Not Applicable

Availability of data and materials: all data are available and sharing is available as well as publication.

Competing interests: The authors hereby that they have no competing interests.

Funding: Corresponding author supplied all study materials. There was no further funding for this study.

Authors' contributions: The authors completed the study protocol and were the primary organizers of data collection and the manuscript's draft and revision process. Tamer A. Addissouky wrote the article and ensured its accuracy. All authors contributed to the discussion, assisted in designing the study and protocol and engaged in critical discussions of the draft manuscript. Lastly, the authors reviewed and confirmed the final version of the manuscript.

Acknowledgements: The authors thank all the researchers, editors, reviewers, and the supported universities that have done great efforts on their studies. Moreover, we are grateful to the editors, reviewers, and reader of this journal.

References

1. AlYousef, A., AlSahow, A., AlHelal, B. et al. (2020). Glomerulonephritis Histopathological Pattern Change. *BMC Nephrol*, 21-186.
2. T A Addissouky, A A Khalil, A E El Agroudy, (2023). Assessment of potential biomarkers for early detection and management of Glomerulonephritis patients with diabetic diseases, *American Journal of Clinical Pathology*, 160(1);18–19.
3. Lim, C.C., Huang, Z. & Choo, J.C.J. (2023). Improving health literacy in disease prevention in glomerulonephritis. *Int Urol Nephrol*, 55; 221–223.
4. Addissouky, T.A., et al. (2020). efficiency of mixture of olive oil and figs as an antiviral agents: a review and perspective, *International Journal of Medical Science and Health Research*, ISSN:2581-3366, 4(4);107-111.
5. Addissouky TA, El Tantawy El Sayed I, Ali MMA, Wang Y, El Baz A, et al. (2024). Shaping the Future of Cardiac Wellness: Exploring Revolutionary Approaches in Disease Management and Prevention. *J Clin Cardiol*.5(1):6-29.
6. Liu, Y., Deng, S.; Song, Z., Zhang, Q., Guo, Y., Zhang, Y. et al. (2021). MLIF Modulates Microglia Polarization in Ischemic Stroke by Targeting EEF1A1. *Frontiers in Pharmacology*, 12.
7. Addissouky TA, Ali MMA, El Tantawy El Sayed I, Wang Y, El Baz A, Elarabany N, et al. (2023). Preclinical Promise and Clinical Challenges for Innovative Therapies Targeting Liver Fibrogenesis. *Arch Gastroenterol Res*, 4(1):14-23.
8. Ameh, O. I., Ekrikpo, U., Bello, A., & Okpechi, I. (2020). Current Management Strategies of Chronic Kidney Disease in

- Resource-Limited Countries. *International Journal of Nephrology and Renovascular Disease*, 13; 239-251.
9. Teo, W. Y., Felicia Chu, S. W., Chow, L. Y., Yeap, C. T., Low, L. L., et al. (2022). Role of Alternative Medical Systems in Adult Chronic Kidney Disease Patients: A Systematic Review of Literature. *Cureus*, 14(12).
 10. Lei, R., Vu, B., Kourentzi, K., Soomro, S., Danthanarayana, A. N., Brgoch, J., Willson, R. C. et al. (2022). A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM. *Frontiers in Immunology*, 13;1044743.
 11. Wang, Y., Wen, Q., Jin, L., & Chen, W. (2022). Artificial Intelligence-Assisted Renal Pathology: Advances and Prospects. *Journal of Clinical Medicine*, 11(16).
 12. Addissouky TA, Ali M, El Tantawy El Sayed I, Wang Y. (2023). Revolutionary Innovations in Diabetes Research: From Biomarkers to Genomic Medicine. *IJDO*; 15 (4) :228-242
 13. Anders, HJ., Kitching, A.R., Leung, N. et al. (2023). Glomerulonephritis: immunopathogenesis and immunotherapy. *Nat Rev Immunol*, 23;453–471.
 14. Saddique, Z., Faheem, M., Habib, A., UIHasan, I., Mujahid, A. et al. (2023). Electrochemical Creatinine (Bio)Sensors for Point-of-Care Diagnosis of Renal Malfunction and Chronic Kidney Disorders. *Diagnostics*, 13(10); 17-37.
 15. Pruijm, M., Aslam, I., Milani, B., Brito, W., & Vallée, J. et al. (2022). Magnetic Resonance Imaging to Diagnose and Predict the Outcome of Diabetic Kidney Disease—Where Do We Stand? *Kidney and Dialysis*, 2(3), 407-418.
 16. Mohammed, E.H., Kaddourah, A., Al Khori, N. et al. (2023). The diagnostic value of DMSA scan in differentiating functional pseudo-tumors from malignancies in scarred kidneys: case series and literature review. *BMC Nephrol*, 24; 148.
 17. Shushunova, N. A., et al. (2023). Targeted Therapy for Glomerulonephritis Using Arterial Delivery of Encapsulated Etanercept. *International Journal of Molecular Sciences*, 24(3); 27-84.
 18. Kawasoe, S., Kubozono, T., Salim, A. A., Yoshimine, H., Mawatari, S., Ojima, S., et al. (2023). Development of a risk prediction score and equation for chronic kidney disease: A retrospective cohort study. *Scientific Reports*, 13(1);1-11.
 19. Aghwana, R., Aiwuyo, H. O., Ovwasa, H., Okoye, O., Kweki, A. G., & Unuigbo, E. et al. (2023). Optimizing Nutrition in Renal Patients: Effects of a Low-Protein Diet Supplemented With Ketoacids. *Cureus*, 15(4).
 20. Weiner, D. E., Liu, C. K., Miao, S., Fielding, R., Katznel, L. I., Giffuni, J., Well, A., & Seliger, S. L. (2023). Effect of Long-term Exercise Training on Physical Performance and Cardiorespiratory Function in Adults With CKD: A Randomized Controlled Trial. *American Journal of Kidney Diseases*, 81(1); 59-66.
 21. Eid, H. A., Moazen, E. M., Elhussini, M., Shoman, H., Hassan, A., Elsheikh, A., et al. (2022). The Influence of Smoking on Renal Functions Among Apparently Healthy Smokers. *Journal of Multidisciplinary Healthcare*, 15; 2969-2978.
 22. Hegazy, M.T., Fayed, A., Nuzzolese, R. et al. (2023). Autoinflammatory diseases and the kidney. *Immunol Res*.
 23. Addissouky, T.A., Wang, Y., Megahed, F.A.K. et al. (2021). Novel biomarkers assist in detection of liver fibrosis in HCV patients. *Egypt Liver*, 11; 86.
 24. Addissouky, T.A., Ayman E. El-Agroudy, Abdel Moneim A.K. El-Torgoman and Ibrahim E. El-Sayed. (2019). Efficacy of Biomarkers in Detecting Fibrosis Levels of Liver Diseases. IDOSI Publications, *World Journal of Medical Sciences*, 16(1): PP. 11-18, ISSN 1817-3055.
 25. Addissouky, T.A., Ayman E. El Agroudy, Abdel Moneim A.K. El-Torgoman, Ibrahim El Tantawy El Sayed, Eman Mohamad Ibrahim et al. (2019). Efficiency of alternative markers to assess liver fibrosis levels in viral hepatitis B patients, Allied Academies Publications, *Biomedical Research*, 30 (2): PP. 351-356.
 26. Addissouky, T.A., (2019). Detecting Liver Fibrosis by Recent Reliable Biomarkers in Viral Hepatitis Patients, *American Journal of Clinical Pathology*, 152(1); 85.
 27. El Agroudy, A. E., Elghareb, M. S., Addissouky, T. A., Elshahat, E. H., & Hafez, E. H. (2016). Serum hyaluronic acid as a non-invasive biomarker to predict liver fibrosis in viral hepatitis patients. *Journal of Biochemical and Analytical Research*, 43(2);108377.
 28. El Agroudy, A. E., Elghareb, M. S., Addissouky, T. A., Elshahat, E. H., & Hafez, E. H. (2016). Biochemical study of some non-invasive markers in liver fibrosis patients. *Journal of Biochemical and Analytical Research*, 43(2); 108375.
 29. T A Addissouky, A E El Agroudy, A A Khalil, (2023). Developing a Novel Non-invasive Serum-based Diagnostic Test for Early Detection of Colorectal Cancer, *American Journal of Clinical Pathology*, 160(1); S17.
 30. Nayak, S., Rehman, T., Patel, K., Dash, P., Alice, A., Kanungo, S., Palo, S. K., & Pati, S. (2023). Factors Associated with Chronic Kidney Disease of Unknown Etiology (CKDu): A Systematic Review. *Healthcare*, 11(4).
 31. Legesse, E. S., Muhammed, O. S., Hamza, L., Nasir, B. B., & Nedi, T. (2022). Medication related problems among ambulatory patients with chronic kidney disease at St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. *Plos One*, 17(12).
 32. Di Leo, V., Annese, F., Papadia, F., Cara, I., Giliberti, M., Sallustio, F., & Gesualdo, L. (2023). The Landscape of IgA Nephropathy Treatment Strategy: A Pharmacological Overview. *Future Pharmacology*, 3(2); 517-534.
 33. Zeng, W., Yang, S., Song, N., & Chu, F. (2022). The impact of angiotensin converting enzyme insertion/deletion gene polymorphism on diabetic kidney disease: A debatable issue. *Nefrología*, 42(4); 415-431.
 34. Windpessl, M., & Kostopoulou, M. (2023). Preventing infections in immunocompromised patients with kidney diseases: vaccines and antimicrobial prophylaxis. *Nephrology Dialysis Transplantation. Advance online publication*.
 35. Teles, F., Coelho, M., Albino, R. M., Verçosa Pacheco, F. C., Duarte Silveira, M. A., M. Feitosa, A. D., & Bezerra, R. (2023). Effectiveness of thiazide and thiazide-like diuretics in advanced chronic kidney disease: A systematic review and meta-analysis. *Renal Failure*, 45(1).
 36. Jacobs, R., Verbrugghe, W., Dams, K., Roelant, E., Couttenye, M. M., Devroey, D., & Jorens, P. (2023). Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy: Is Metabolic Fear the Enemy of Logic? A Systematic Review and Meta-Analysis of Randomised Controlled Trials. *Life*, 13(5);1198.
 37. Kronbichler A, Bajema I, Geetha D, et al. (2023). Novel aspects in the pathophysiology and diagnosis of glomerular diseases *Annals of the Rheumatic Diseases*, 82; 585-593.
 38. Sawaf, H., Gudura, T. T., Dorobisz, S., Sandy, D., Wang, X., & Bobart, S. A. (2023). Genetic Susceptibility to Chronic Kidney Disease: Links, Risks and Management. *International Journal of Nephrology and Renovascular Disease*, 16; 1-15.

39. Alallam, B., Choukaife, H., Seyam, S., Lim, V., & Alfatama, M. (2023). Advanced Drug Delivery Systems for Renal Disorders. *Gels*, 9(2); 115.
40. Khalid, H., Khan, A., Khan, M. Z., Mehmood, G., & Qureshi, M. S. (2023). Machine Learning Hybrid Model for the Prediction of Chronic Kidney Disease. *Computational Intelligence and Neuroscience*.
41. Alamilla-Sanchez, M. E., Alcalá-Salgado, M. A., Alonso-Bello, C. D., & Fonseca-Gonzalez, G. T. (2022). Mechanism of action and efficacy of immunosuppressors in lupus nephritis. *International Journal of Nephrology and Renovascular Disease*, 14; 441-458.
42. Shima, H., Doi, T., Okamoto, T. et al. (2023). Successful treatment of nephrotic syndrome due to pregnancy-related crescentic IgA nephropathy: a case report. *BMC Nephrol*, 24;92.
43. Turgut, F., Awad, A. S., & M., E. (2023). Acute Kidney Injury: Medical Causes and Pathogenesis. *Journal of Clinical Medicine*, 12(1); 375.
44. Lee, G., Joo, J., Kim, Y., Choi, H., Boo, K. Y., Hwang, Y., Hur, H., & Jeong, M. H. (2023). Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction. *Plos One*, 18(3); e0281460.
45. Kalay, Z., Sahin, O. E., Copur, S., Danaci, S., Ortiz, A., Yau, K., Cherney, D. Z., & Kanbay, M. (2023). SGLT-2 inhibitors in nephrotic-range proteinuria: Emerging clinical evidence. *Clinical Kidney Journal*, 16(1); 52-60.
46. Ku, E., et al. (2023). Novel Anemia Therapies in Chronic Kidney Disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney International*.
47. Huijben, J. A., et al. (2023). Increasing numbers and improved overall survival of patients on kidney replacement therapy over the last decade in Europe: An ERA Registry study. *Nephrology Dialysis Transplantation*, 38(4); 1027-1040.
48. Jankowski, E., Schlosser, M., Wiech, T. et al. (2023). SARS-CoV-2 infection: a possible trigger for the recurrence of IgA nephropathy after kidney transplantation?. *J Nephrol*.
49. Bai, J., Zhang, T., Wang, Y., Cao, J., Duan, Z., Ji, L., Zhou, Y., Hao, C., & Guo, Q. (2023). Incidence and risk factors for recurrent focal segmental glomerulosclerosis after kidney transplantation: A meta-analysis. *Renal Failure*, 45(1).
50. Longhitano, E., et al. (2023). Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine. *Cancers*, 15(6);1891.
51. Krisanapan, P., Tangpanithandee, S., Thongprayoon, C., Pattharanitima, P., & Cheungpasitporn, W. (2023). Revolutionizing Chronic Kidney Disease Management with Machine Learning and Artificial Intelligence. *Journal of Clinical Medicine*, 12(8).
52. Qin X, Xia L, Zhu C, Hu X, Xiao W, Xie X, Zhang C. (2023). Noninvasive Evaluation of Lupus Nephritis Activity Using a Radiomics Machine Learning Model Based on Ultrasound. *J Inflamm Res*, 16; 433-441.
53. Wang, B., Kim, K., Tian, M., Kameishi, S., Zhuang, L., Okano, T., & Huang, Y. (2023). Engineered Bone Marrow Stem Cell-Sheets Alleviate Renal Damage in a Rat Chronic Glomerulonephritis Model. *International Journal of Molecular Sciences*, 24(4); 3711.
54. Xu, K., Han, Y., Huang, Y., Wei, P., Yin, J., & Jiang, J. (2022). The application of 3D bioprinting in urological diseases. *Materials Today Bio*, 16; 100388.
55. Mason, W. J., Jafree, D. J., Pomeranz, G., Kolatsi-Joannou, M., Rottner, A. K., Vasilopoulou, E. et al. (2022). Systemic gene therapy with thymosin β 4 alleviates glomerular injury in mice. *Scientific Reports*, 12.
56. Singh, J., Singh, S. (2023). Review on kidney diseases: types, treatment and potential of stem cell therapy. *Ren Replace Ther* 9, 21 (2023).
57. Yang, Z., Xu, H., Gou, S. et al. (2023). Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report. *BMC Nephrol*, 24;145.
58. Wooden, B., Tarragon, B., & Bomback, A. S. (2023). Complement inhibitors for kidney disease. *Nephrology Dialysis Transplantation*.
59. Addissouky, T.A., Sayed, I.E.T.E., Ali, M.M.A. et al. (2024). Latest advances in hepatocellular carcinoma management and prevention through advanced technologies. *Egypt Liver Journal*, 14; 2.
60. Addissouky, T.A., Wang, Y., El Sayed, I.E. et al. (2023). Recent trends in Helicobacter pylori management: harnessing the power of AI and other advanced approaches. *Beni-Suef Univ J Basic Appl Sci*, 12; 80.
61. T A Addissouky, A A Khalil, (2023). Detecting Lung Cancer Stages Earlier by Appropriate Markers Rather Than Biopsy and Other Techniques, *American Journal of Clinical Pathology*, 154(1); S146–S147.
62. Shushunova, N. A., et al. (2023). Targeted Therapy for Glomerulonephritis Using Arterial Delivery of Encapsulated Etanercept. *International Journal of Molecular Sciences*, 24(3); 2784.
63. Kyllies, D., et al. (2023). Expansion-enhanced super-resolution radial fluctuations enable nanoscale molecular profiling of pathology specimens. *Nature Nanotechnology*, 18(4);336-342.
64. Maali, A., Gholizadeh, M., Noei, A., Sheila, S., Mansoori, S., & Sharifzadeh, Z. (2023). Nanobodies in cell-mediated immunotherapy: On the road to fight cancer. *Frontiers in Immunology*, 14;1012841.
65. Sargazi, S., Arshad, R., Ghamari, R., Rahdar, A., Bakhshi, A., Karkan, S. F., Ajalli, N., & Bilal, M. (2022). siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review. *Cell Biology International*, 46(9); 1320-1344.
66. Jiang, B., Zhang, Y., Li, Y., Chen, Y., Sha, S., Zhao, L., Li, D., Wen, J., Lan, J., Lou, Y., Su, H., Zhang, C., Zhu, J., & Tao, J. (2022). A Tissue-Tended Mycophenolate-Modified Nanoparticle Alleviates Systemic Lupus Erythematosus in MRL/Lpr Mouse Model Mainly by Promoting Local M2-Like Macrophages Polarization. *International Journal of Nanomedicine*, 17; 3251-3267.
67. Addissouky TA, El Tantawy El Sayed I, Ali MMA, Wang Y, El Baz A, Khalil AA, et al. (2023). Can Vaccines Stop Cancer Before It Starts? Assessing the Promise of Prophylactic Immunization Against High-Risk Preneoplastic Lesions *J Cell Immunol*, 5(4):126-127.
68. Fabrizi, F., Donato, M. F., Tripodi, F., Regalia, A., Lampertico, P., & Castellano, G. (2023). The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights. *Pathogens*, 12(2); 340.
69. Thammathiwat, T., Banjongjit, A., Iampenkhae, K., Townamchai, N., & Kanjanabuch, T. (2023). ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review. *Vaccines*, 11(5); 983.
70. Addissouky, T.A., Yuliang Wang, Ibrahim El Tantawy El Sayed et al. (2023). Probiotics and Diet Modifications: A Holistic Approach to Tackling Helicobacter pylori with the Help of the Gut Microbiota.

71. Yuan, T., Xia, Y., Li, B. et al. (2023). Gut microbiota in patients with kidney stones: a systematic review and meta-analysis. *BMC Microbiol*, 23;143.
72. T A Addissouky, A A Khalil, A E El Agroudy, (2023). Assessing the Efficacy of a Modified Triple Drug Regimen Supplemented with Mastic Gum in the Eradication of Helicobacter pylori Infection, *American Journal of Clinical Pathology*, 160(1);19.
73. Addissouky TA, Ali MMA, El Tantawy El Sayed I, Wang Y. (2023). Recent Advances in Diagnosing and Treating Helicobacter pylori through Botanical Extracts and Advanced Technologies. *Arch Pharmacol Ther*, 5(1);53-66.
74. Chen, Hongyu; Cheng, Qingli. (2023). Therapeutic Effects of Jin Shui Bao Capsules on Kidney Diseases. *Integrative Medicine in Nephrology and Andrology*, 10(1); e00025.
75. Nayak, S., Rehman, T., Patel, K., Dash, P., Alice, A., Kanungo, S., Palo, S. K., & Pati, S. (2023). Factors Associated with Chronic Kidney Disease of Unknown Etiology (CKDu): A Systematic Review. *Healthcare*, 11(4); 551.
76. Odler, B., Bruchfeld, A., Scott, J., Geetha, D., Little, M. A., Jayne, D. R., & Kronbichler, A. (2023). Challenges of defining renal response in ANCA-associated vasculitis: Call to action? *Clinical Kidney Journal*, 16(6); 965-975.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

Submit Manuscript

DOI: [10.31579/2690-8794/199](https://doi.org/10.31579/2690-8794/199)

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <https://auctoresonline.org/journals/clinical-medical-reviews-and-reports>